BCMA/FcRL5 TriTE / Coding Bio - LARVOL DELTA

An AI-Designed BCMA/FcRL5 Targeting TriTE Overcomes Antigen Escape and Outperforms BCMA-Directed Therapy in Multiple Myeloma (IMS 2026) - "Cytotoxicity was further enhanced in BCMA-knockout cells engineered to overexpress FcRL5; in this setting, CB-101 outperformed both Teclistamab and Cevostamab. CB-101, a BCMA/FcRL5 TriTE, demonstrated enhanced antitumor activity in vitro and in vivo, outperforming BCMA-directed therapy even at substantially lower doses and retaining efficacy in settings associated with antigen escape and drug resistance. Enabled by an AI-driven high-throughput discovery platform, this next-generation BCMA/FcRL5 TriTE with provocative preclinical data is now poised for clinical evaluation in MM and WM to improve outcomes."

IO biomarker • Hematological Disorders • Hematological Malignancies • Lymphoma • Lymphoplasmacytic Lymphoma • Multiple Myeloma • Waldenstrom Macroglobulinemia

A NEXT-GENERATION FCRL5/BCMA TRISPECIFIC ANTIBODY DEMONSTRATES SUPERIOR ACTIVITY OVER BISPECIFIC CONSTRUCTS AND SUPPORTS CLINICAL DEVELOPMENT IN B-CELL MALIGNANCIES (EHA 2026) - "In the disseminated U266 B1 MM model, dose-escalation studies showed that TriTE achieved superior antitumor activity at a 10-fold lower dose than Teclistamab and prolonged survival; median survival: 62 days for control, 82 days for Teclistamab while all TriTE-treated mice remained alive beyond 130 days, consistent with durable responses in this model. . Summary/Conclusion Leveraging a high-throughput discovery platform, we have generated BCMA/FcRL5 TriTE antibodies with superior antitumor activity and increased in vivo potency, outperforming BCMA-directed therapy even at lower doses in vivo. These results support dual-antigen targeting as a strategy to overcome the limitations of BCMA-only approaches and provide a strong rationale for clinical translation of our BCMA/FcRL5 TriTE in MM and WM."

Bispecific • Clinical • IO biomarker • Trispecific • Hematological Malignancies • Lymphoma • Lymphoplasmacytic Lymphoma • Multiple Myeloma • Waldenstrom Macroglobulinemia • GPRC5D